Positive Phase 3 results for brodalumab

|By:, SA News Editor

The AMAGINE-1 Phase 3 clinical trial evaluating brodalumab for the treatment of moderate-to-severe plaque psoriasis meets all primary and secondary endpoints for both doses. Brodalumab is a human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammation by blocking the binding of several IL-17 ligands to the receptor.

The primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12 measured by PASI 75 and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment (sPGA 0 or 1).

AMAGINE-1 is one of three clinical trails to assess the safety and efficacy of brodalumab. AMAGINE-2 and -3 are trials to evaluate brodalumab versus ustekinumab and placebo.

Brodalumab is one of five mAbs from Amgen's (AMGN +0.6%) clinical inflammation portfolio that it is developing with AstraZeneca (AZN -1.9%) in a collaboration that began in 2012.